Helsinn Healthcare S.A. v. Accord Healthcare, Inc. et al.

I'll research this case and the underlying patents.

Case Overview & Background

Parties. This is a Hatch-Waxman ANDA case, not an NPE/PAE or university assertion. Plaintiff Helsinn Healthcare S.A. is a privately held, family-controlled Swiss pharmaceutical company (Lugano) that holds NDA No. 021372 for Aloxi® (palonosetron hydrochloride injection), an antiemetic used to prevent chemotherapy-induced nausea and vomiting; it is an operating innovator company that commercializes the drug through partners (originally MGI Pharma, later Eisai). Co-plaintiff Roche Palo Alto LLC is the successor to Syntex and the originator of the palonosetron chemistry; it licensed the palonosetron portfolio to Helsinn in 1998 and co-owned the formulation patents, and its Rule 7.1 disclosure identified Roche Holdings/Roche Finance/Novartis as parents (D.I. 2–3, Dec. 27, 2013). Defendants were Accord Healthcare, Inc., the U.S. generic arm (Durham, NC) of India's Intas Pharmaceuticals Ltd., an ANDA sponsor that filed a Paragraph IV certification against the Orange Book–listed Aloxi patents.

Accused product and patents. The accused conduct is Accord's ANDA submission (with Paragraph IV certifications) seeking approval to market a generic 0.25 mg/5 mL palonosetron HCl intravenous solution — i.e., a generic Aloxi — before expiry of the listed patents; infringement is pleaded solely under 35 U.S.C. § 271(e)(2)(A), with accompanying §§ 271(a)–(c) declarations. The complaint as filed on Dec. 27, 2013 asserted two patents, both titled Liquid Pharmaceutical Formulations of Palonosetron and both issued three weeks earlier on Dec. 3, 2013:

• U.S. 8,598,219 — a single-use, unit-dose 5 mL sterile aqueous isotonic IV formulation comprising 0.25 mg palonosetron HCl (free base), 0.005–1.0 mg/mL EDTA, and 10–80 mg/mL mannitol, "wherein said formulation is stable at 24 months when stored at room temperature" (claim 1; claim 8 is the 18-month variant).
• U.S. 8,598,218 — a sibling continuation in the same family claiming the liquid formulation in concentration terms (the family's 0.05 mg/mL palonosetron / EDTA / mannitol / room-temperature-stability concept; I did not retrieve the '218 claim text, so I am not quoting it).
• U.S. 7,947,725 — the same family's earlier-issued formulation claim (intravenous palonosetron at 0.05 mg/mL with EDTA and mannitol, stable at room temperature). Important nuance: the AO-120 report filed with this complaint lists only the '218 and '219, and contemporaneous reporting describes the suit as asserting only those two. The '725 and the later-issued '729,094 entered this docket through amended pleading/consolidation — the June 2014 stipulation permitted amended complaints adding the '094 and dropping the '218 and '851,981 claims with prejudice (D.I. 56, ¶¶ 1–3). I could not retrieve the amended complaint itself, so the precise reconfiguration is inferred from the docket.

Posture, venue, and outcome. Filed in the U.S. District Court for the District of Delaware, Wilmington, before Chief Judge Gregory M. Sleet (C.A. No. 13-2101-GMS). Helsinn expressly justified Delaware personal jurisdiction on Accord's prior consent to jurisdiction and assertion of counterclaims there, and on Intas's contacts through Accord (Compl. ¶¶ 12–14) — the same foreign-parent jurisdiction problem that was roiling ANDA venue practice post-Daimler. Intas was dismissed without prejudice by stipulation filed Jan. 31, 2014 and so ordered Feb. 25, 2014, leaving Accord as sole defendant. Accord moved to dismiss under Rule 12(b)(6) on Feb. 6, 2014 (D.I. 10–11), which was fully briefed; the parties stipulated that the court's ruling on that motion "will apply equally" to the '094 patent. On June 17, 2014 the court consolidated this case for all purposes with Nos. 13-688, 13-1612 and 14-427 (all papers to be filed in 13-688). The case terminated Nov. 25, 2014 — one day after the PTAB terminated Accord's post-grant review, in the same week the parties' confidential settlement was filed. Accord and Helsinn settled; the docket does not reflect a merits judgment.

Why it is notable. Three reasons. (1) Early PGR history: Because the '219 was filed as a continuation-in-part on May 23, 2013 and its claims depended on newly added matter, it was an AIA patent and therefore PGR-eligible — and Accord's petition (PGR2014-00010, filed Sept. 2, 2014) was, per Patent Docs, only the second PGR ever filed, attacking claims 1–5 and 8 of the '219 under §§ 102/103 and, notably, § 112 (written description/enablement). That made this dispute an early test case for whether PGRs would be a viable pharma validity vehicle; it was cut short by settlement (Judgment, Paper 10, Nov. 24, 2014, granting the joint motion

I'll research this case across the docket, court opinions, Federal Circuit, and PTAB records.

Let me pull the full docket and related records.

Let me get the full docket text and the PGR details.

Helsinn Healthcare S.A. v. Accord Healthcare, Inc., C.A. No. 1:13-cv-02101-GMS (D. Del.)

Bottom line: This was a short-lived Hatch-Waxman ANDA case. It ran roughly eleven months, from a December 2013 complaint asserting the newly issued '218/'219 palonosetron patents, through a Rule 12(b)(6) motion and a mid-2014 consolidation + patent swap (adding the '094 patent, dropping '218 with prejudice), to a sealed consent judgment in November 2014 that terminated the case. There was no Markman ruling, no trial, no verdict, and no appeal in this docket. The single PTAB proceeding Accord filed (a PGR in September 2014) was terminated by joint motion as part of the same settlement, roughly four days after the consent judgment was signed.

---

Chronological developments

---

1. Filing and initial pleadings

Helsinn Healthcare S.A. and Roche Palo Alto LLC filed suit on 2013-12-27 under 35 U.S.C. § 271(e)(2)(A), targeting Accord's ANDA No. 204615 for generic 0.25 mg/5 mL palonosetron hydrochloride IV solution (Aloxi®). Notably, the complaint asserted only the '218 and '219 patents, both of which had issued just three weeks earlier on 2013-12-03 — a classic "newly issued patent, no Paragraph IV certification yet" theory. The complaint pleaded that the '218 patent "had not issued at the time Defendants made their § 505(j)(2)(A)(vii)(IV) certification" and that Accord was legally required either to amend its ANDA to certify against '218 or abandon the pre-expiration approval request. See Complaint, D.I. 1.

Jurisdictional allegations tracked Accord's prior consents to Delaware jurisdiction and Intas's agreement to be bound through Accord — see D.I. 1 at ¶¶ 13–14.

The case cover sheet recorded patent expiration 2024-01-30 and a 30-month stay deadline of 2015-04-13. Docket report shows Patent Docs, 2014-01-06.

Intas exited on consent almost immediately. On 2014-01-31 the parties stipulated to dismissal of Intas without prejudice and to amend the caption; Judge Sleet so ordered it on 2014-02-25. Intas is therefore terminated as of Feb. 2014 and played no further role.

No answer or counterclaims were ever filed by Accord in this docket. Accord waived service (due 2014-04-01) but responded with a motion to dismiss rather than an answer, and the case settled before any answer was required. This is a notable contrast with the co-pending Delaware actions, where Aurobindo and Cipla did assert invalidity/non-infringement counterclaims over the '724, '725, '424, '981, '218, and '219 patents (see the recitals in the June 17, 2014 stipulation).

2. Pre-trial motions of substance

(a) Accord's Rule 12(b)(6) motion to dismiss (filed 2014-02-06). D.I. 10, with opening brief at D.I. 11. The motion is fully briefed — D.I. 11 (opening), sealed D.I. 15 (opposition, 2/24/2014), D.I. 18 (reply), D.I. 20–22 (request for oral argument and related papers). The motion was never decided on the merits. The June 17, 2014 stipulation expressly provided that the Court's eventual ruling on it "will apply equally to the '094

I'll research the counsel of record for Helsinn in this D. Del. action.

Counsel of Record for Plaintiffs (Helsinn Healthcare S.A. and Roche Palo Alto LLC)

Caveat up front: In this action the plaintiffs were Helsinn Healthcare S.A. and Roche Palo Alto LLC jointly (Helsinn alone appears in the case metadata; Roche Palo Alto was a co-plaintiff in the complaint filed 12/27/2013). No in-house counsel appears as counsel of record on the docket — all appearances are outside counsel. The case did not go to judgment on the merits in 13‑2101: it was consolidated for all purposes into C.A. No. 13‑688‑GMS (Helsinn v. Cipla/Aurobindo/Ben Venue) by stipulation in June 2014, and the 13‑2101 docket was closed on 11/25/2014. Later filings by these counsel appear on the 13‑688 docket. (Stipulation, D.I. 56 in 13‑2101)

Also worth flagging as a records discrepancy: the complaints in 13‑2101 asserted the '218 and '219 patents (and later the '094 patent by amendment), while the '725 patent belonged to the companion consolidated action 13‑688. The '725 listing in the case metadata is best read as a function of the consolidation.

---

Delaware counsel of record — Morris, Nichols, Arsht & Tunnell LLP (Wilmington, DE)

Source for both: CourtListener parties/docket page, Helsinn Healthcare S.A. v. Accord Healthcare Inc., 1:13‑cv‑02101. Signature blocks in the consolidated-case stipulation list Blumenfeld and Noreika as "[a]ttorneys for Plaintiffs." (D.I. 56, 13‑2101)

Of counsel — Paul Hastings LLP (New York, NY) — for Helsinn Healthcare S.A.

Listed under "OF COUNSEL" on plaintiffs' filings in this consolidated family, i.e., the substantive/lead patent team behind the Delaware local counsel:

Of counsel — Loeb & Loeb LLP (New York, NY) — for Roche Palo Alto LLC

Sources for the Paul Hastings / Loeb & Loeb of‑counsel blocks: plaintiffs' stipulation and amended-pleading signature blocks in the consolidated Delaware actions (D.I. 56; D.I. 119, 13‑688‑GMS), and identical blocks on the palonosetron complaints filed in D.N.J. (complaint excerpt).

---

Caveats / limits on sourcing

• The 13‑2101 docket sheet itself is only partially visible to me. CourtListener's party page for 13‑2101 confirms only Blumenfeld (lead) and Noreika (terminated 2018) as plaintiffs' counsel of record. The Paul Hastings and Loeb & Loeb lawyers are documented as "Of Counsel" in signed filings in this consolidated case family, but I could not independently verify each of the six Paul Hastings names as a separately entered ECF appearance on the 13‑2101 docket rather than on the consolidated 13‑688 docket. Treat the of‑counsel list as accurate for the litigation team, with the appearance-by-appearance detail unverified.
• No in-house counsel (Helsinn or Eisai) appears as counsel of record; in-house representatives appear only as protective-order designees.
• I found no sealing order affecting the appearances themselves — counsel listings here are from public filings — but the case settled/resolved without a merits judgment in 13‑2101, so there is no trial-team roster from a verdict to cross-check against.
• Per your instruction, case metadata (caption, number, patents) is taken as authoritative even where third-party databases (e.g., DrugPatentWatch, which lists only '218/'219 and a 2014‑11‑25 termination) differ.

I'll research the docket and counsel for Accord/Intas in this D. Del. case.

Counsel of Record — Defendants Accord Healthcare, Inc. & Intas Pharmaceuticals Ltd.

Helsinn Healthcare S.A. v. Accord Healthcare, Inc., No. 1:13-cv-02101-GMS (D. Del., filed Dec. 27, 2013; terminated Nov. 2014)

Two firms appeared for the defense: Young Conaway Stargatt & Taylor LLP (Delaware local counsel) and Greenblum & Bernstein, P.L.C. (Reston, VA — national/Hatch-Waxman counsel of record). Both defendants were represented by the same team; Intas was dismissed by stipulation on Feb. 25, 2014 (D.I. 7), so it had no separate counsel of record of its own. No in-house counsel appears on the docket.

Sourcing and caveats

• CourtListener/RECAP parties page for No. 1:13-cv-02101 lists Accord as represented by Adam Wyatt Poff (Young Conaway, 302-571-6600) and Monte Terrell Squire, both marked “ATTORNEY TO BE NOTICED / LEAD ATTORNEY”; Intas is shown as terminated Feb. 25, 2014. https://www.courtlistener.com/docket/[4220368](/patent/4220368)/parties/helsinn-healthcare-sa-v-accord-healthcare-inc/
• Docket entries confirmed: D.I. 1 (Complaint, Dec. 27, 2013); D.I. 7 (stipulation dismissing Intas without prejudice and amending caption, so ordered by Chief Judge Gregory M. Sleet, Feb. 25, 2014); D.I. 10 (Accord's Rule 12(b)(6) motion); an early-2014 PHV motion for “Neil M. Greenblum, Michael J. Fink, Jill M. Browning, Paul A. Braier, Ph.D., and P. Branko Pejic” filed by Accord; D.I. 56 (June 2014 stipulation consolidating 13-688, 13-1612, 13-2101 and 14-427 before Judge Sleet, dropping the '218/'981 claims with prejudice and adding the '094 patent).
• Signature blocks in Accord's filings confirm the two-firm structure: “Adam W. Poff, Esquire; Monté T. Squire, Esquire, YOUNG, CONAWAY, STARGATT & TAYLOR LLP … Attorneys for Accord Healthcare, Inc.” and “Neil F. Greenblum, Esquire; Michael J. Fink, Esquire; Paul A. Braier, Ph.D.; P. Branko Pejic, Esquire; Jill M. Browning, Esquire, GREENBLUM & BERNSTEIN, P.L.C., 1950 Roland Clarke Place, Reston, VA 20191” (see, e.g., the Jan. 24, 2014 certificate of service at storage.courtlistener.com/recap/gov.uscourts.ded.49359.72.0.pdf, and D.I. 56 in No. 13-2101-GMS).
• The G&B–Accord pairing recurs in the companion Helsinn/Cipla action (No. 14-427-GMS), where the complaint's counsel block lists the same G&B team “Attorneys for Defendant Accord Healthcare, Inc.”
• Not verified: the orders granting the PHV motions (I saw the motion, not the signed order), any withdrawal appearances by G&B attorneys after the November 2014 consent judgment, and current firm affiliations for Messrs. Fink and Pejic. Nothing in this docket appears to have been sealed as to counsel identity, so the above reflects the public record.

Related note on Intas

Intas never filed a separate appearance. Its dismissal was stipulated to by Accord's Delaware counsel (Poff) on behalf of both defendants, consistent with the complaint's allegation that Accord is Intas's U.S. subsidiary and that the two act in concert on ANDAs. Accord also separately petitioned for post-grant review of the '219 patent in Sept. 2014 (PGR filed 2014-09-02 naming Accord as petitioner), a proceeding handled by the same G&B team.